Kornimate/medical-research-clean huggingface dataset:
neuroglove anxiety and depression study

Conditions: Anxiety; Depression; Anxiety Depression; Depression, Anxiety

Summary: this is a prospective, homebased, interventional clinical study containing 10 subjects who will be enrolled. approximately 10 (10) subjects with active anxiety and depression symptoms will receive treatment using the neuroglove.

this is a prospective, homebased, interventional clinical study containing 10 subjects who will be enrolled. approximately 10 (10) subjects with active anxiety and depression symptoms will receive treatment using the neuroglove. subjects will be recruited in from the community. inclusion in the study will not impact the care management of the subject. informed consent will be obtained from all subjects before inclusion in the study.

Eligibility criteria:
inclusion criteria: * able to and willing to provide informed consent. legally authorized representatives (lars) will not be allowed to consent on behalf of the subject. * men and women ≥18 and \<85 years of age. * carry an active diagnosis of anxiety and/or depression. * suffer from anxiety and/or depression symptoms that impact subject's daily activities and quality of life. exclusion criteria: * physical limitations of the upper extremity (e.g., fracture, joint deformity, severe spasticity/contracture, wounds, skin breakdown, lymphedema, etc.) * the subject lacks the ability to comprehend or following instructions, or for any reason, in the opinion of the investigator, would be unlikely or unable to comply with study protocol requirements. * currently participating in another interventional clinical trial. (observational clinical trial participation is allowed for study enrollment.)

Keywords: anxiety depression
validation of a screening scale for misuse of opioid analgesics

Conditions: Cancer; Pain; Opioid Analgesic Adverse Reaction

Summary: in oncology, pain is one of the main symptoms of discomfort. it has a significant impact on the quality of life.the use of opioid analgesics is recommended for the treatment of moderate to severe cancer pain.the misuse of opioid analgesics is an international public health problem.different scales have been developed to help the prescriber screen for the risk of misuse in the general population. patients with cancer-related pain are also at risk for aberrant opioid-related behaviors, misuse or addiction. the main objectif of this study is to validate of the screening scale for the misuse of opioid analgesics in patients with chronic pain related to cancer. (prescription opioid misuse index - pomi).

the study takes place in 2 phases. test phase : questionnaire no. 1 constitutes the data for the test phase: it includes socio-demographic data, medical and family history, lifestyle, treatments, 5 questions from the concise pain questionnaire (qcd), the french version of the pomi scale, the diagnostic criteria of the dsm-v and two questions concerning anxiety associated with pain and therapeutic education. retest phase : questionnaire no. 2 10 to 15 days later.

Eligibility criteria:
inclusion criteria: * patients aged 18 and over, * patients with chronic cancer-related pain that has been evolving for at least 3 months, * patients with a regular prescription of at least one opioid analgesic medicine taken daily for at least 1 month, * patients followed in oncology for an active cancerous pathology. exclusion criteria: * stopping opioid prescriptions on the day of the test phase (no retest possible), * patients in the process of weaning (risk of being weaned during the retest phase), * patients unable to complete the questionnaire on their own, * patients followed in a pain or addiction centre, * patients in terminal palliative situations of their cancer, * patients with chronic pain that is more disabling than cancer-related pain, * patients refusing to participate, * patients under guardianship or curatorship, * pregnant or breastfeeding patients, * patient with a language barrier limiting understanding of the questionnaire in french.
the role of probiotics in the eradication of helicobacter pylori

Conditions: Helicobacter Pylori Infection

Summary: all patients will receive quadruple eradication therapy for 10 days with omerazole 20mg x2, amoxicilin 1g x2, clarithromycin 500mg x2 and metronidazole 500mg x2. the patients will be randomised into two groups. the first group will receive one capsule of probiotics x2 two hours before or after meal for 15 days and the second group placebo (capsule with same composition and colour with probiotic) x2, two hours before or after meal for 15 days as well. the probiotic (lactolevure, uni-pharma, athens) contains four probiotic strains known for their effectivness and safety, saccharomyces boulandrii (1.5 bu/capsule), bifidobacterium lactis bb-12 (1.75 bu/capsule), lactobacillus acidodophilus la-5 (1.75 bu/capsule) and lactobacillus plantarum (0.5 bu/capsule).

patients with h.pylori infection establised after a uper gi endoscopy and gastric biopsy will receive quadruple eradication therapy for 10 days with omerazole 20mg x2, amoxicilin 1g x2, clarithromycin 500mg x2 and metronidazole 500mg x2. the patients will be randomised into two groups. the first group will receive one capsule of probiotics x2 two hours before or after meal for 15 days and the second group placebo (capsule with same composition and colour with probiotic) x2, two hours before or after meal for 15 days as well. the probiotic contains four probiotic strains known for their effectivness and safety, saccharomyces boulandrii (1.5 bu/capsule), bifidobacterium lactis bb-12 (1.75 bu/capsule), lactobacillus acidodophilus la-5 (1.75 bu/capsule) and lactobacillus plantarum (0.5 bu/capsule). patients will report in a specific questionnare the presence or absence of symptoms suggestive of side effects associated with the abx administered (i.e flatulance, abdominal pain, diarrhoea, regurgitation, vomiting). all patints will be subjected to urea breath test one month after the completion of treatment in order to verify hp eradication.

Eligibility criteria:
inclusion criteria: * established helicobacter pylori infection exclusion criteria: * pregnancy * lactate * previous eradication therapy for hp. * course of antibiotics and/or probiotics one month prior to stydy entry * course of ppi's, h2- antagonst and antacids two weeks prior to study entry * known allergy to antibiotics that will be used in study * coronary disease, heart failure,malignancy,thyroid disease, pulmonary disease or other serious disease as per medical judgment

Keywords: helicobacter pylori probiotics eradication treatment of h.pylori antibiotics proton pump inhibitors saccharomyces boulardii bifidobacterium lactis lactobacillus acidophilus lactobacillus plantarum
biomarkers derived from adipose tissue useful for diagnosis and prognosis of cardiovascular risk (cvr) in obese patient

Conditions: Metabolic Syndrome; Diabetes Mellitus; Inflammatory Response

Summary: this study evaluates the relationship between the adipose tissue, as an active component, which can define metabolic phenotypes linked to cardiovascular risk modification post bariatric surgery.

bariatric surgery induces a significant reduction in co-morbidities associated with obesity, such as diabetes mellitus, dyslipidemia, liver disease, arterial hypertension, obstructive apnea and cardiovascular risk. however this does not happen in all obese patients, even when there is a weight reduction. it is known that the adipose tissue is actively involved in synthesis of cytokines and its role in metabolic phenotypes has been suggested. it is possible that the intrinsic mechanisms of adipose tissue participate in several benefits observed in morbidly obese patients who undergo to an anti-obesity surgery. so this study explores the involvement of adipose tissue as an active component, which can define metabolic phenotypes linked to cardiovascular risk modification post bariatric surgery.

Eligibility criteria:
inclusion criteria: * above 18 years old. * morbid obese patients candidates to bariatric surgery. exclusion criteria: * second bariatric surgery

Keywords: adipose tissue, cardiovascular, obese patients
levulan pdt versus vehicle for extremity actinic keratoses (ak)

Conditions: Keratosis, Actinic

Summary: the purpose of this study is to determine if levulan pdt is safe and effective in the treatment of actinic keratoses on the upper arms and hands.


Eligibility criteria:
inclusion criteria: * at least 4 grade 1/2 aks on each upper extremity exclusion criteria: * pregnancy * history of cutaneous photosensitization, porphyria, hypersensitivity to porphyrins or photodermatosis * lesions suspicious for skin cancer (skin cancer not ruled out by biopsy) or untreated skin cancers within the treatment area * skin pathology or condition which could interfere with the evaluation of the test product or requires the use of interfering topical or systemic therapy * subject is immunosuppressed * unsuccessful outcome from previous ala-pdt therapy * currently enrolled in an investigational drug or device study * has received an investigational drug or been treated with an investigational device within 30 days prior to the initiation of treatment * known sensitivity to one or more of the vehicle components (ethyl alcohol, isopropyl alcohol, laureth 4, polyethylene glycol) * use of the following topical preparations on the extremities to be treated: * keratolytics including urea (greater than 5%), alpha hydroxyacids \[e.g.glycolic acid, lactic acid, etc. greater than 5%\], salicylic acid (greater than 2%) within 2 days of initiation of treatment. * cryotherapy within 2 weeks of initiation of treatment * retinoids, including tazarotene, adapalene, tretinoin, retinol, within 4 weeks of initiation of treatment. * microdermabrasion, laser ablative treatments, ala-pdt, chemical peels, 5-fu, diclofenac, imiquimod or other topical treatments for ak within 8 weeks of initiation of treatment. * two or more ala pdt treatments in the past 6 months * use of systemic retinoid therapy within 6 months of initiation of treatment.

Keywords: actinic keratosis
educational module and decision counseling program in increasing mammography screening rates in formerly homeless women with serious mental illness

Conditions: Breast - Female

Summary: this pilot clinical trial studies how well an educational module and decision counseling program works in increasing mammography screening rates in formerly homeless women with serious mental illness. an educational module and decision counseling program may be an effective tool and have the potential to help with early detection and treatment.

primary objectives: i. increase mammography screening rates in women age 40 and over with experiences of homelessness and serious mental illness (smi). ii. increase knowledge, decease psychological distress, and advance decision stage and intention to get a mammogram in study participants.

Eligibility criteria:
inclusion criteria: * 30 formerly homeless women with a diagnosis of a serious mental illness in the pathways to housing or project home supportive housing programs * only women that have never received a mammogram are eligible to participate (self-report) * participants must be willing to participate in all aspects of research exclusion criteria: * participants cannot be decisionally impaired, actively psychotic, or have unstable mental illness that prevents participation in the decisional counseling session * women who have had a mammogram will be excluded from the study
divided dose of travatan®

Conditions: Open-angle Glaucoma; Ocular Hypertension

Summary: the purpose of this study is to compare the incremental dosing of travoprost ophthalmic solution versus once a day dosing of travatan® in lowering intraocular pressure (iop) in patients with open-angle glaucoma (oag) or ocular hypertension (oht).


Eligibility criteria:
inclusion criteria: * patients with open-angle glaucoma or ocular hypertension who meet the following iop criteria: 1. mean iop ≥ 24 mmhg in at least 1 eye, with the same eye qualifying at 8 am at both day 0 and day 1; 2. mean iop ≤ 36 mmhg in both eyes at all time points on day 0 and day 1. * must sign an informed consent form. * other protocol-defined inclusion criteria may apply. exclusion criteria: * females of childbearing potential who are pregnant, test positive on urine pregnancy test at the screening visit, intend to become pregnant during the study period, are breast-feeding, or are not using highly effective birth control measures. * current or history of ocular inflammation or infection in either eye within the past 3 months. * corneal thickness greater than 620 µm as determined by pachymetry in either eye. * severe visual field loss. * cup to disc ratio greater than 0.8 in either eye. * intraocular surgery within the past 6 months in either eye. * other protocol-defined exclusion criteria may apply.

Keywords: open-angle glaucoma ocular hypertension divided dose
compare the pharmacokinetics and safety of ckd-333 with co-administration ckd-330 and d090 in healthy male adults

Conditions: Hypertension; Dyslipidemias

Summary: the object of clinical trial is to investigate the pharmacokinetics and safety compared to ckd-333 and co-administration ckd-330, d090 under fasting condition in healthy male adults.

an open-label, randomized, fasted, single-dose, three-way crossover study to compare the pharmacokinetic characteristics and safety between administration of ckd-333 and coadministration of ckd-330 and d090 in healthy male adults

Eligibility criteria:
inclusion criteria: 1. healthy male adults aged 19 to 45 years 2. body weight more than 50kg and within ideal body weight ±20% 3. signed informed consent form exclusion criteria: 1. have clinical significant medical history or disease that cardiovascular system, respiratory system, kidney, endocrine system, hematological system, digestive system , mental illness 2. have a gastrointestinal disease history that can effect drug absorption or surgery 3. systolic blood pressure≥140mmhg or systolic blood pressure\<90mmhg, diastolic blood pressure≥90mmhg or diastolic blood pressure\<60mmhg
thoracic re-irradiation for locoregionally recurrent non-small cell lung cancer

Conditions: Loco-regionally Recurrent NSCLC After Thoracic Radiotherapy

Summary: this prospective phase ii study is to assess the efficacy and safety of thoracic re-irradiation for locoregionally recurrent non-small cell lung cancer using hypofractionated technique.

this prospective phase ii study is to assess the efficacy and safety of thoracic re-irradiation for locoregionally recurrent non-small cell lung cancer using hypofractionated technique. 1. for peripherally located recurrent tumors, stereotactic body radiation therapy is used at 5000-6000 cgy in 10 fractions. 2. for centrally located recurrent tumors, adaptive hypofractionated radiation is used: patients are irradiated at 3000-4000cgy in 6-10 daily fractions in the first course. after a four-week interval, patients who have non-progressive disease and an adequate pulmonary function undergo adaptive re-planning, and are irradiated at 2400-3500cgy in 4\~7 daily fractions as a boost. concurrent chemotherapy consists of weekly docetaxel and nedaplatin.

Eligibility criteria:
inclusion criteria: * loco-regionally recurrent nsclc after thoracic radiotherapy (confirmed by pathology or continuous enhanced ct imaging); * chemotherapy, targeted or immunotherapy are allowed before enrollment; * \>=6 months from previous chest radiotherapy; * presence of measurable disease according to recist criteria; * ecog performance score is 0-1; * organ and bone marrow functions meet the following criteria: * forced expiratory volume in 1 second (fev1) ≥ 0.8l; * percentage-predicted single-breath carbon monoxide diffusing capacity (dlco %) \> 60%; * absolute neutrophil count ≥1.5×10\^9/l; * platelet ≥80×10\^9/l; * hemoglobin ≥9.0g/dl; * serum creatinine clearance was ≥50 ml/min calculated based on the cockcroft-gault formula * serum bilirubin ≤1.5 times normal upper limit (uln) * ast and alt≤2.5 times uln exclusion criteria: * previous or concurrent with other malignant tumors, except for non-melanoma of the skin or carcinoma in situ of the cervix; * loco-regional recurrence with distant metastasis; * any other disease or condition contradicted to radiotherapy (e.g., active infection, within 6 months after myocardial infarction, symptomatic heart disease, including unstable angina, congestive heart failure or uncontrolled arrhythmia, immunosuppressive therapy); * women who are pregnant or breastfeeding, women who have not undergone a pregnancy test (within 14 days before first administration), and women who are pregnant; * pregnancy, lactation, or fertility but no contraceptive measures; * those with bleeding tendency; * participate in other clinical trials within 30 days before enrollment; * drug and other drug addiction, chronic alcoholism and aids patients; * having uncontrollable seizures or loss of self-control due to psychosis; * a history of severe allergies; * participants considered unfit to participate in this study.

Keywords: loco-regionally recurrent non-small cell lung cancer thoracic irradiation hypofraction
study on baroreceptor function in relation to orthostatic blood pressure regulation after hip surgery

Conditions: Hypotension, Orthostatic; Total Hip Replacement

Summary: the purpose of this observational study is to evaluate the baroreceptor function in relation to surgical inflammation and orthostatic intolerance after elective hip arthroplasty. the main hypothesis is that baroreceptor function is attenuated after surgery and related to surgical inflammation.

orthostatic intolerance and hypotension is prevalent during early mobilization after major surgery. this observational study aims to evaluate the baroreceptor function during using a standardized evaluation protocol before, 6- and 24 hours after elective primary unilateral hip-arthroplasty. the study hypothesis is that baroreceptor function as expressed by the valsalva ratio is attenuated after surgery and related to surgical inflammation.

Eligibility criteria:
inclusion criteria: * scheduled for unilateral hip arthroplasty * 18 years or older * able to give informed consent exclusion criteria: * american society of anesthesiologists (asa) class 3 or higher * chronic arrythmia (atrial fibrillation or other arrythmia) * incompensated ischaemic heart disease * mobilization restriction due to surgical reasons * medical complications during admission requiring transferral to other department

Keywords: postoperative orthostatic intolerance surgical inflammatory response
a non-randomized study of internal radiation therapy to the liver in patients with primary liver cancer for whom surgery is not possible.

Conditions: Liver Cancer

Summary: surgical resection of the affected liver offers the best chance for disease-free survival in patients with hepatoma (hcc). unfortunately, most hepatoma patients present with disease which is multi-focal and thus not resectable. fewer than 15% of hcc patients are resectable. the objective of treatment with therasphere is to selectively administer a dose of radioactive material directly to neoplastic tissue in the liver. systemic therapy is largely ineffective.

protocol objectives include: * determine the proportion of patients with hcc in whom the treatment plan can be completed * evaluate the response to therapy * evaluate toxicities and adverse experiences associated with therasphere treatment * evaluate survival time

Eligibility criteria:
inclusion criteria: * over 18 years of age of any sex, race * histological proof of hcc * able to give informed consent * ecog performance equal or less than 2 * life expectancy equal to or greater than 3 months * non- pregnant with acceptable contraception in premenopausal women * greater than 4 weeks since prior radiation therapy or surgery * 1 month post chemotherapy * serum bilirubin \< 2.0 * acceptable white blood count exclusion criteria: * co-morbid disease that would place patient at undue risk. * pre-existing diarrhea/illness * pregnant * fail preliminary maa testing

Keywords: liver cancer brachytherapy
sensory intervention for children with autism

Conditions: Autism Spectrum Disorder

Summary: greater than 80% of children with autism spectrum disorder (asd) experience sensory differences that make it difficult for them to fully participate in meaningful everyday activities. in this research study, we will use mri and behavioral methods to assess how sensory interventions might change sensory brain structures, allowing us to better predict which sensory interventions might work best for whom.


Eligibility criteria:
inclusion criteria: male children 6 years, 0 months to 8 years, 6 months of age with a diagnosis of autism spectrum disorder (asd) will qualify for inclusion. our inclusion age ensures all study participants will complete intervention/control conditions and be retested before they turn 9 years of age. additional inclusion criteria include: 1. the families of children will have access to transportation to attend intervention sessions 2 times per week for 16-weeks. 2. children who qualify will be verbal, and will speak and understand english. the native language of caregivers can include spanish. 3. children who qualify will have sensorimotor delays as assessed by the study team using the standardized, norm-referenced assessments described in this research proposal (z-scores on 3 of 5 tests -1.0 or lower). exclusion criteria: children younger than 6 years of age or older than 8 years, 6 months of age will be excluded. additional exclusion criteria include: 1. female children 2. auditory hyperresponsivity as assessed during screening procedures. 3. medical co-morbidities such as extreme prematurity (less than 28 weeks), blindness, deafness, cerebral palsy, down syndrome, tuberous sclerosis, or head-injury with loss of consciousness. 4. history of individual occupational therapy services in a clinical setting that includes sensory equipment. 5. non-removable metal in the head or body (e.g. dental fillings \& braces, metal pins, screws or plates). 6. children unable to complete neurocognitive or sensorimotor testing. 7. children unsuccessful in 3 mock scanning sessions during baseline testing.